Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Aging
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Rapamycin 1mg for 8 weeksMasking: None (Open Label)Primary Purpose: Basic Science
Participation Requirements
- Age
- Between 70 years and 95 years
- Gender
- Only males
Description
The main study has completed and results are reported (NCT02874924) Purpose of Sub-study E - Rapamycin and cMRI to evaluate cardiac function: The over-arching hypothesis is that RAPA treatment will effect simultaneous improvement in parameters known to be negatively impacted by aging. For example, s...
The main study has completed and results are reported (NCT02874924) Purpose of Sub-study E - Rapamycin and cMRI to evaluate cardiac function: The over-arching hypothesis is that RAPA treatment will effect simultaneous improvement in parameters known to be negatively impacted by aging. For example, systemic inflammation is higher in older individuals and contributes to the development of age-related pathologies affecting both the heart and the vasculature. In particular, evidence indicates that aging-associated alterations in inflammatory and pro-fibrotic pathways are critically involved in the etiology of age-related declines. The study team hypothesize that mTOR antagonism with RAPA will improve detrimental age-related pathologies affecting the heart in elderly humans.
Tracking Information
- NCT #
- NCT04742777
- Collaborators
- The Claude D. Pepper Older Americans Independence Centers
- Investigators
- Principal Investigator: Dean L Kellogg, Jr., MD PhD The University of Texas Health Science Center at San Antonio
Get Well Soon